Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes.

Autor:	Raniga K; The Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK; Pathology, Non-Clinical Safety, GlaxoSmithKline R&D, Stevenage SG1 2NY, UK. Electronic address: kh.raniga@gmail.com., Nasir A; The Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK., Vo NTN; The Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK., Vaidyanathan R; FUJIFILM Cellular Dynamics, Inc., Madison, WI, USA., Dickerson S; FUJIFILM Cellular Dynamics, Inc., Madison, WI, USA., Hilcove S; FUJIFILM Cellular Dynamics, Inc., Madison, WI, USA., Mosqueira D; The Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK., Mirams GR; Centre for Mathematical Medicine & Biology, School of Mathematical Sciences, University of Nottingham, Nottingham NG7 2RD, UK., Clements P; Pathology, Non-Clinical Safety, GlaxoSmithKline R&D, Stevenage SG1 2NY, UK., Hicks R; BioPharmaceuticals R&D Cell Therapy Department, Research and Early Development, Cardiovascular, Renal, and Metabolism (CVRM), BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden; School of Cardiovascular and Metabolic Medicine & Sciences, King's College London, London WC2R 2LS, UK., Pointon A; Safety Sciences, Clinical Pharmacology and Safety Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK., Stebbeds W; LifeArc, Stevenage SG1 2FX, UK., Francis J; Mechanstic Biology and Profiling, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge CB2 0AA, UK., Denning C; The Biodiscovery Institute, University of Nottingham, Nottingham NG7 2RD, UK. Electronic address: chris.denning@nottingham.ac.uk.
Jazyk:	angličtina
Zdroj:	Cell stem cell [Cell Stem Cell] 2024 Mar 07; Vol. 31 (3), pp. 292-311. Date of Electronic Publication: 2024 Feb 15.
DOI:	10.1016/j.stem.2024.01.007
Abstrakt:	Advances in hiPSC isolation and reprogramming and hPSC-CM differentiation have prompted their therapeutic application and utilization for evaluating potential cardiovascular safety liabilities. In this perspective, we showcase key efforts toward the large-scale production of hiPSC-CMs, implementation of hiPSC-CMs in industry settings, and recent clinical applications of this technology. The key observations are a need for traceable gender and ethnically diverse hiPSC lines, approaches to reduce cost of scale-up, accessible clinical trial datasets, and transparent guidelines surrounding the safety and efficacy of hiPSC-based therapies. Competing Interests: Declaration of interests R.V., S.D., and S.H. are employees of FUJIFILM Cellular Dynamics International. Peter Clements is an employee of GlaxoSmithKline. R.H., A.P., and J.F. are employees of AstraZeneca. W.S. is an employee of LifeArc. (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu